Admin Control Panel

New Post | Settings | Change Layout | Edit HTML | Edit posts | Sign Out

Scroll down and select country
MEBO TMAU TESTING CURRENTLY SUSPENDED INDEFINITELY

MEBO - UBIOME study 2018

'PRESS RELEASE'

NCT03582826
ClinicalTrials.gov

MEBO Gut Microbiome Study
"Microbial Basis of Systemic Malodor and PATM Conditions (PATM)"
Funded by uBiome Research Grant

"Microbial Basis of Systemic Malodor and PATM Conditions (PATM)"

Dynamics of the Gut Microbiota in
Idiopathic Malodor Production
& PATM

Started May 2018 - Ongoing

Current people sent kits : 100/100
3 kits per person

NO LONGER RECRUITING

Participation info : LINK English

MEBO Map Testing & Meetups


Full details : https://goo.gl/TMw8xu
want listed ? contact info@meboresearch.org

MEBO Private Facebook Group
to join : go to
or contact
Join/Watch the weekly
BO Sufferers Podcasts

MEBO TMAU Videos

Petitions

TMAU Petition world
TMAU UK end total:262
TMAU UK ends 23/01/20
TMAU Petition USA end total 204
USA : Moveon open
TMAU (Dominican)
Metabolomic Profiling Study
NCT02683876

Start : Aug 2016
Stage 1 : 27 Canadian volunteers to test
Latest click here (26 oct) :
17 samples returned


Note : Stage 1 is Canada only.
Return cut-off date : passed
Analysis can take 6/8 weeks
Analysis start in/before Nov
MEBO Research is a
EURORDIS and
NORD Member Organization
See RareConnect

Popular Posts (last 30 days)

Upcoming get-togethers


Let us know if you want a meetup listed

Subscribe to Blog

Enter your email address:

Delivered by FeedBurner

You will be sent a verification email

Subscribe in a reader

Blog Archive

MEBO Research Clinical Trials

Click here to read details of the MEBO Clinical Trials
NCT03582826 - Ongoing not recruiting
Microbial Basis of Systemic Malodor and PATM Conditions (PATM)
United States 2018 - ongoing

NCT02683876 - Completed
Exploratory Study of Relationships Between Malodor and Urine Metabolomics
Canada and United States 2016 - ongoing

NCT03451994 - Completed
Exploratory Study of Volatile Organic Compounds in Alveolar Breath
United Kingdom and United States 2013 - ongoing

NCT02692495 - Completed
Evaluation of Potential Screening Tools for Metabolic Body Odor and Halitosis
United Kingdom 2009 - 2012

Thursday, October 31, 2019

Gene Editing and FMO3 : cure in 5-10-15 years ?

Ultimately, the cure for FMO3 Genetic Malodor (e.g. TMAU1) will be Gene Therapy.
The question is, when ?
Probably sooner than expected.

Gene therapy is where they can correct errors in the code.
A bit like word-processor correcting, or correcting with copy and paste.

There are various gene-editors, but the 'big game-changer one' seems to be CRISPR ... first published about in 2012.
Last week a new paper was published that spoke of an improvement which makes 'single letter' correcting of DNA safer and easier.
Most people with FMO3 flaws will have 'single letter' (base) flaws.

Prof Jennifer Doudna, the co-founder of CRISPR said in 2015 :
She expects clinical therapies within 10 years (so 2025 ?)
 
Current obstacles with gene-editing to overcome :
Probably safety, precision, worry about side effects ?, delivery to the body, cost, no human trials yet etc

CRISPR is cheap to do in a test tube, but delivery to the body, licencing cost etc will be dear to start with probably. 

FMO3 most common types of gene flaws.
Most with 'sub-par' FMO3 (either always, or transiently), will be due to NUCLEOTIDE MISSENSE  errors.
This is to do with A,G,T,C.
FMO3 protein is a 532 amino acid sequence.
The DNA will be 3 nucleotides on each side to make up the amino acid (532x3x2 letter code).
Like AA AG TC etc.
Most FMO3 people will have one of those letters wrong, making the amino acid incorrect at that codon (532 rung ladder of codons).
Examples : E308G E158K  V257M
These 3 mistakes are common, but most FMO3 people seem to carry 2 of the mistakes (either at same codon, or as a mix)

So these flaws should technically be easy to fix when the technology is ready (?)
They say the easiest type to fix are :
single gene : tick ... FMO3
single base flaws  : ... most FMO3 people have these

Has FMO3 ever been tried in CRISPR ?
It seems a Chinese lab experimented with mice in 2015 re FMO3.
Probably proving the principle for FMO3.
Chinese paper 2015 FMO3 knock-in/knock-out in mice. 
No follow up seemed to happen.
Probably as FMO3 is regarded as not an important gene, and 'sufferers' are rare (an incorrect assumption).

Where would FMO3 treated cells be delivered to the body ?
Probably the liver.
FMO3 is in a lot of places in the body, but mainly in the liver.
Sickle-cell anemia is being looked at now for CRISPR treatment, as they can take blood out and treat it. But they have to put it back in the bone marrow.
No human clinical trials have been completed yet.

Dr David Lui paper from Oct 2019 
Dr Lui of Harvard seems to have improved the CRISPR targeting for base mistakes (? base editing)
It has been tweeted by peers, so seems a breakthrough.
new gene-editing technique may be capable of fixing almost all disease-causing genetic defects 

So, whatever happens re FMO3 smells and/or TMAU, keep in mind the genetic type may be close to being genetically cured in 5-10-15 years (or sooner ... as many gene disorders will be).

Notable People to search in Gene-Editing and CRISPR world (from skim-reading about CRISPR)
Prof Jennifer Doudna (oct19 article)
Prof Emmanuelle Charpentier
Prof Feng Zhang
Prof George Church
Dr David Lui
... many more.

get New Posts by EMAIL : Enter your email address :



A EURORDIS and NORD Member Organization

0 comments:

Post a Comment